Table 4.
Factors for treatment decision making in OMD
| Synchronous OMD (prostate) | Rating (mean)* | Oligorecurrent disease (colorectal) | Rating (mean)* | Oligoprogressive disease (lung) | Rating (mean)* |
|---|---|---|---|---|---|
| Number of metastases | 4.634 | Number of metastases | 4.568 | Risk of toxicity from local treatment or systemic therapy | 4.444 |
| Risk of toxicity from local treatment or systemic therapy | 4.488 | Patient preference | 4.459 | Number of metastases | 4.333 |
| Patient preference | 4.463 | Risk of toxicity from local treatment or systemic therapy | 4.432 | Patient symptoms/quality of life | 4.306† |
| Primary cancer histology | 4.341 | Comorbidities and performance status | 4.378 | Patient preference | 4.306† |
| Comorbidities and performance status | 4.268 | Patient symptoms/quality of life | 4.324 | History of treatments for metastatic sites | 4.200 |
| Patient symptoms/quality of life | 4.122 | Primary cancer histology | 4.189 | Comorbidities and performance status | 4.111 |
| Locoregional versus distant metastases | 4.073 | Time to progression | 4.162 | Time to progression | 4.056 |
| Osseous versus extraosseous location | 4.000 | History of treatments of primary cancer | 4.135 | Patient age | 4.028‡ |
| Extracranial versus intracranial location | 3.927 | Locoregional versus distant metastases | 3.865 | History of treatments of primary cancer | 4.028‡ |
| Benefit of increased time off systemic therapy | 3.610 | Patient age | 3.838 | Primary cancer histology | 3.944 |
| Extent of primary tumor | 3.561 | Risk of harm due to delay of systemic therapy | 3.703 | Extracranial versus intracranial location | 3.833 |
| Patient age | 3.390 | Benefit of increased time off systemic therapy | 3.676 | Locoregional versus distant metastases | 3.750 |
| Biomarkers of primary cancer | 3.293§ | Extracranial versus intracranial location | 3.541 | Osseous versus extraosseous location | 3.639 |
| Risk of harm due to delay of systemic therapy | 3.293§ | Osseous versus extraosseous location | 3.459 | Risk of harm due to delay of systemic therapy | 3.600 |
| Nodal versus nonnodal involvement | 3.171 | Extent of primary tumor | 3.243║ | Biomarkers of primary cancer | 3.583 |
| Cost | 2.512 | Biomarkers of primary cancer | 3.243║ | Extent of primary tumor | 3.389 |
| Nodal versus nonnodal involvement | 3.189 | Benefit of increased time off systemic therapy | 3.314 | ||
| Cost | 2.649 | Nodal versus nonnodal involvement | 3.194 | ||
| Cost | 2.694 |
Abbreviation: OMD = oligometastatic disease.
⁎
Likert scale scoring: 1 = strongly disagree, 2 = somewhat disagree, 3 = neutral, 4 = somewhat agree, 5 = strongly agree.
†,‡,§,║
Equal average score.